Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.
CancerNetwork® sat down with Paolo Ghia, MD, from the Universita Università Vita-Salute San Raffaele, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the CAPTIVATE trial (NCT02910583) examining the chemotherapy-free regimen of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL). With the all-oral therapy regimen, patients experienced promising progression-free survival and overall survival.
Transcript:
This [regimen] is really opening a new way of treating patients with chronic lymphocytic leukemia, because so far we are used to continuing treatment, which [has] revolutionized the treatment in CLL. With the advent of oral therapies, [patients] indeed experienced increases in the progression-free survival and overall survival. Of course, having a fixed-duration treatment might be very beneficial for our patient because that would allow [us] to stop the treatment after a number of months, preventing the long-term adverse events, but also the possibility of the occurrence gene mutations and therefore resistance to the drugs.
Reference
Ghia P, Allan J, Siddiqi T et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 39;2021(suppl 15):7501. doi: 10.1200/JCO.2021.39.15_suppl.7501
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.